Saturday, January 2, 2016
Verisante Provides Operational Update
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec 21, 2015) - Verisante Technology, Inc. (TSX VENTURE:VRS)(VRSEF) (the "Company" or "Verisante"), a leader in skin cancer detection technology, provides an operational update.
Verisante is pleased to announce the Company has placed an Aura™ at the Restore Vein and Skin Centre in Kelowna, BC ("Restore"). Restore is a preeminent facility for skin health and cosmetic medicine servicing patients in Kelowna and the Okanagan Valley. The Clinic's guiding principle of employing evidenced-based medicine and bestpractice guidelines establishes the foundation for the very best patient care.
"We are excited to be able to offer Aura™ to the public at the Restore Vein and Skin Centre," said Dr. Henry Docherty. "Skin cancer is the most common type of all cancers with a growing incidence rate. We believe Aura™ will be an excellent tool to help us save lives through the early diagnosis and detection of skin cancer."
Aura™ has also been gaining acceptance in Germany, led by Drs. at the HighLine Clinic in Bremen, who will be hosting an informational event for General Practitioners in Germany aimed at educating front line medical professionals on achieving better patient outcomes through the integrating Aura™ into their practice.
In addition to the market penetration being made with Aura™, the Company also continues to make progress with applications for Verisante's Core™ system for the detection of internal cancers.
Earlier in 2015, the Company announced a collaboration between Verisante, the BC Cancer Agency and Imperial College Healthcare NHS Trust to develop an application that would use Verisante's Core™ laser raman system in a study to determine if the system is able to assist in ascertaining the margins between tumour and normal brain tissue. The initial results have been very encouraging as the study continues to enroll new patients. The study is being led by Dr. Babar Vaqas, a Neurosurgeon and the Principal Investigator.
Verisante also announced today that the Company has closed a non-brokered private placement of 4,000,000 units consisting of one common share and one share purchase warrant at a price of $0.05 per unit for gross proceeds of $200,000. The warrants shall have a term of three years and an exercise price of $0.08 per share.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking StatementsThis release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.